I am reaching out to you to share our excitement over Biosight’s proposed merger with Advaxis, Inc. (Nasdaq: ADXS) and explain why we believe the transaction represents a mutually compelling ...
MONMOUTH JUNCTION, N.J. and AIRPORT CITY, Israel, July 06, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (“Advaxis”) (NASDAQ: ADXS) and Biosight Ltd. (“Biosight”), a privately held pharmaceutical development ...
"We are very pleased to have received from the FDA the Orphan Drug Designation for aspacytarabine for the treatment of MDS, which adds to the designation granted already for the treatment of AML" said ...
AIRPORT CITY, Israel, June 4, 2019 /PRNewswire/ -- Biosight Ltd., a pharmaceutical development company focused on the development of novel oncology therapeutics, announced today that the United States ...
AIRPORT CITY, Israel, Nov. 22, 2022 /PRNewswire/ -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced ...
Combined company to operate as Ayala Pharmaceuticals, Inc. Merger to add a clinical stage oncology asset to Ayala’s portfolio with data anticipated in the first half of 2024 REHOVOT and TEL AVIV, ...
AIRPORT CITY, Israel, May 18, 2021 (GLOBE NEWSWIRE) -- ., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced the ...
Biosight, an Israeli pharmaceutical development company that is working on a cure for leukemia, this week closed an investment of $13 million led by pharmaceutical investment firm Arkin Holdings, run ...
(BUSINESS WIRE)-- Bionext, a bioinformatics company, announces today the launch of BioSight, an online bio-simulation platform designed for efficient identification of possible side effects of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results